Arthroplasty, Replacement, Hip Clinical Trial
Official title:
A Prospective, Post-market, Multi-center Study of the Outcomes of the Rejuvenate® Modular Hip System
NCT number | NCT01257568 |
Other study ID # | 68 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | November 2010 |
Est. completion date | January 20, 2022 |
Verified date | February 2022 |
Source | Stryker Orthopaedics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will be an evaluation of the Rejuvenate® Modular Hip System for primary total hip replacement (THR) with a cementless application in a consecutive series of patients who meet the eligibility criteria. Subjects will be evaluated for freedom of hip revision at 5 years and clinical outcomes for up to 10 years after surgery.
Status | Completed |
Enrollment | 42 |
Est. completion date | January 20, 2022 |
Est. primary completion date | June 6, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient has signed an IRB approved, study specific Informed Patient Consent Form. - Patient is a male or non-pregnant female age 18 years or older at time of study device implantation. - Patient has primary diagnosis of Non-Inflammatory Degenerative Joint Disease (NIDJD). - Patient is a candidate for a primary cementless total hip replacement. - Patient is willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation. - Patient's operative femur templates to Rejuvenate® Modular Stem size 7-12. Exclusion Criteria: - Patient has a Body Mass Index (BMI) = 40. - Patient has an active or suspected latent infection in or about the affected hip joint at time of study device implantation. - Patient has a neuromuscular or neurosensory deficiency, which limits the ability to evaluate the safety and efficacy of the device. - Patient is diagnosed with a systemic disease (e.g. Lupus Erythematosus) or a metabolic disorder (e.g. Paget's Disease) leading to progressive bone deterioration. - Patient is immunologically suppressed or receiving steroids in excess of normal physiological requirements (e.g. > 30 days). - Patient requires revision surgery of a previously implanted total hip replacement or hip fusion to the affected joint. - Patient has a known sensitivity to device materials. - Patient is a prisoner. |
Country | Name | City | State |
---|---|---|---|
United States | Oakwood Healthcare | Dearborn | Michigan |
United States | St. Cloud Orthopaedics Associates | Sartell | Minnesota |
United States | The Orthopedic Center | Tulsa | Oklahoma |
Lead Sponsor | Collaborator |
---|---|
Stryker Orthopaedics |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Survival Rate of the Rejuvenate Modular Stem/Neck | The success rate is defined as freedom from Rejuvenate Modular femoral stem/neck construct revision/removal for any reason. | 5 years postoperative | |
Secondary | Biomechanical Measurement of Femoral Offset | Change from Preoperative Natural Femoral Offset to Postoperative Femoral Offset at 6-weeks postoperative measured in millimeters. | 6 weeks | |
Secondary | Biomechanical Measurement of the Vertical Distance of the Planned Hip Center of Rotation | Change from preoperative vertical distance of the anatomic hip center to the planned center of rotation of the hip to the postoperative distance from the planned center of rotation at 6 weeks measured in millimeters. | 6 weeks | |
Secondary | Biomechanical Measurement of the Horizontal Distance of the Planned Hip Center of Rotation | Change from preoperative horizontal distance of the anatomic hip center to the planned center of rotation of the hip to the postoperative distance from the planned center of rotation at 6 weeks measured in millimeters. | 6 weeks | |
Secondary | Mean Harris Hip Score at Each Visit | The Harris Hip Score (HHS) assesses pain, function, joint deformity and range of motion. Scores can range from 0 to 100 with 0 being the worst and 100 being the best score. A score of 80-100 is considered good-excellent and a score of less than or equal to 79 is considered fair-poor.
90-100 = excellent 80-89 = good 70-79 = fair 0-69 = poor |
pre-op, 6 wk, 1, 2, 3, 4, 5, 7 year | |
Secondary | Mean SF-12 Scores at Each Visit | The SF-12 Health Survey is a 12-item patient completed questionnaire to measure general health and well-being. It includes a physical and mental status component score; each ranging from 0-100. Low values represent a poor health state and high values represent a good health state. | pre-op, 6 wk, 1, 2, 3, 4, 5, 7 year | |
Secondary | Mean Lower Extremity Activity Scale (LEAS) Scores at Each Visit | The LEAS is completed by the participant to assess activity level. Activity levels were ordered in terms of intensity from 1 to 18, with 18 indicating the highest activity level. | pre-op, 6 wk, 1, 2, 3, 4, 5, 7 year | |
Secondary | Occurrence of Subsidence at Six Weeks, Stem Migration, Unstable Fixation and Radiographic Instability (Radiolucency) | Radiographic stability of the stem is defined as having the following: no radiographic indication of progressive radiolucent lines greater than or equal to 2 mm around the entire femoral component, and no radiographic indication of progressive subsidence of the femoral component of great than or equal to 5 mm. Only subsidence was measured at 6 weeks, migration and fixation are analyzed beginning at 1 year postoperative. | 6 wks,1,2,3,4,5 yrs |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Recruiting |
NCT03746925 -
Comparing Short-term Outcomes After Direct Anterior and SuperPATH Hip Arthroplasty Approaches
|
N/A | |
Completed |
NCT03008967 -
A Study of Patients Undergoing Total Knee and Hip Arthroplasty at a Regional Hospital in Denmark
|
N/A | |
Not yet recruiting |
NCT00958945 -
Retrospective Chart Analysis in the Effective Use of FloSeal in Post-Operative Joint Replacements
|
N/A | |
Completed |
NCT00980616 -
Use of Local Analgesia With Epinephrine During Total Hip Arthroplasty (THA)
|
Phase 2 | |
Completed |
NCT04542174 -
PMCF 8 Year Results TRJ®
|
||
Not yet recruiting |
NCT04019925 -
Assessing the Wear Rates of the ADM/MDM Hips Using 3D X-ray Analysis
|
N/A | |
Recruiting |
NCT06102811 -
Low Concentration Local Anesthesia Fascia Iliaca Block for Total Hip Arthroplasty
|
N/A | |
Recruiting |
NCT03570944 -
Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol (POWER2)
|
||
Recruiting |
NCT02938962 -
Intravenous vs. Topical Tranexamic Acid in Revision THA (VITALITY-X)
|
Phase 4 | |
Completed |
NCT03076827 -
Effects of Surgery Start Time on Postoperative Interleukin-6, Interleukin-8, and Cortisol
|
N/A | |
Recruiting |
NCT02385383 -
An Intravenous Iron Based Protocol for Preoperative Anaemia in Hip and Knee Surgery - An Observational Study
|
N/A | |
Completed |
NCT01444586 -
Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE)
|
N/A | |
Terminated |
NCT02525627 -
A Comparative Study of In-vivo Wear Between 28 mm and 40 mm Metal Heads
|
N/A | |
Completed |
NCT00808483 -
Walking Skill Training Program Effects in Patients With Total Hip Arthroplasty
|
N/A | |
Terminated |
NCT00958347 -
Omnifit Hydroxylapatite (HA) Hip Outcomes Study
|
N/A | |
Completed |
NCT01422304 -
Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)
|
Phase 3 | |
Completed |
NCT04332055 -
RCT Measuring the Effect of the ERVIN Software
|
N/A | |
Recruiting |
NCT01031732 -
Evaluation of Four Surgical Techniques in Primary Total Hip Arthroplasty
|
N/A | |
Completed |
NCT00797264 -
Ketamine Associated With Morphine PCA After Total Hip Arthroplasty
|
N/A |